These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 3871589)

  • 61. The clinical use of aztreonam.
    Schönwald S; Schoss-Vidensek Z; Car V; Krznar B
    Chemotherapy; 1989; 35 Suppl 1():45-8. PubMed ID: 2731450
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Resistance to beta-lactams in gram-negative bacteria: relative contributions of beta-lactamase and permeability limitations.
    Nayler JH
    J Antimicrob Chemother; 1987 Jun; 19(6):713-32. PubMed ID: 3301784
    [No Abstract]   [Full Text] [Related]  

  • 63. The action of some beta-lactam antibiotics on the penicillin-binding proteins of Gram-negative bacteria.
    Curtis NA; Orr DC; Boulton MG
    Philos Trans R Soc Lond B Biol Sci; 1980 May; 289(1036):368-70. PubMed ID: 6109334
    [No Abstract]   [Full Text] [Related]  

  • 64. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of beta-lactamase on minimum inhibitory concentrations of methicillin in methicillin-resistant Staphylococcus aureus.
    Sasatsu M; Miyazawa K; Noguchi N; Kono M
    Microbios; 1994; 78(316):145-53. PubMed ID: 8041291
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trends in the development of beta-lactam antibiotics.
    Neu HC
    Scand J Infect Dis Suppl; 1984; 42():7-16. PubMed ID: 6597563
    [TBL] [Abstract][Full Text] [Related]  

  • 67. How and why aztreonam works.
    Rittenbury MS
    Surg Gynecol Obstet; 1990; 171 Suppl():19-23. PubMed ID: 2244291
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.
    Yang Y; Bhachech N; Bush K
    J Antimicrob Chemother; 1995 Jan; 35(1):75-84. PubMed ID: 7768785
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Empiric antibiotic use--aztreonam as a model.
    Levin S
    Am J Med; 1990 Mar; 88(3C):21S-23S; discussion 38S-42S. PubMed ID: 2316555
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Aztreonam activity, pharmacology, and clinical uses.
    Neu HC
    Am J Med; 1990 Mar; 88(3C):2S-6S; discussion 38S-42S. PubMed ID: 2180293
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro activity and beta-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents.
    Neu HC; Labthavikul P
    Antimicrob Agents Chemother; 1983 Aug; 24(2):227-32. PubMed ID: 6605715
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.
    Sanders CC; Sanders WE
    Rev Infect Dis; 1983; 5(4):639-48. PubMed ID: 6353526
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
    Henry SA; Bendush CB
    Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Spectrum of Thiazolidinediones against Respiratory Tract Pathogenic Bacteria: An In Vitro and In Silico Approach.
    Al Bratty M; Hakami AQ; Masmali HA; Alam MS; Alhazmi HA; Thangavel N; Najmi A; Moni SS; Haque A
    Curr Pharm Biotechnol; 2020; 21(14):1457-1469. PubMed ID: 32552647
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections.
    Rodriguez JR; Ramirez-Ronda CH
    Am J Med; 1985 Feb; 78(2A):42-3. PubMed ID: 4038578
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical experience with aztreonam in four Mediterranean countries.
    Daikos GK
    Rev Infect Dis; 1985; 7 Suppl 4():S831-5. PubMed ID: 2934787
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Review of the clinical pharmacology of the monobactam antibiotic aztreonam.
    Swabb EA
    Am J Med; 1985 Feb; 78(2A):11-8. PubMed ID: 3881946
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Conjugation of Aztreonam, a Synthetic Monocyclic β-Lactam Antibiotic, to a Siderophore Mimetic Significantly Expands Activity Against Gram-Negative Bacteria.
    Liu R; Miller PA; Miller MJ
    ACS Infect Dis; 2021 Nov; 7(11):2979-2986. PubMed ID: 34668698
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthesis and Antibacterial Activities of Amidine Substituted Monocyclic β-Lactams.
    Zhai L; He L; Liu Y; Myo KK; Iqbal Z; Sun J; Ji J; Ji J; Mu Y; Gao Y; Tang D; Yang H; Yang Z
    Med Chem; 2022; 18(5):574-588. PubMed ID: 34463230
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Aztreonam plus clindamycin as therapy for pelvic infections in women.
    Pastorek JG; Cole C; Aldridge KE; Crapanzano JC
    Am J Med; 1985 Feb; 78(2A):47-50. PubMed ID: 4038579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.